HLA-A*24:02-restricted Up-regulated in lung cancer 10 (URLC10) (HLA-A*24:02/URLC10)

Up-regulated in lung cancer 10 (URLC10) is a cancer-testis antigen (CTA) that is significantly overexpressed in a variety of malignancies, including non-small cell lung cancer, esophageal cancer, and pancreatic cancer, while remaining largely silent in normal adult tissues except for the testis [1][2]. The HLA-A*24:02-restricted URLC10-derived peptide (specifically the URLC10-243 epitope) is presented by the HLA-A*24:02 allele, which is particularly common in East Asian populations, making it a highly relevant target for regional precision immunotherapy [3][4]. This peptide-MHC complex acts as a beacon for the immune system, allowing for the induction of specific cytotoxic T lymphocytes (CTLs) that can selectively recognize and destroy tumor cells expressing the antigen [5]. Therapeutic strategies, such as the S-288310 peptide vaccine, leverage this mechanism by administering the URLC10 peptide, often in combination with other tumor-associated antigens like VEGFR1, to stimulate a robust anti-tumor immune response [6]. Clinical evaluations have shown that targeting this complex is feasible and can elicit measurable immune responses in patients with advanced-stage cancers [1][7].

Other names

HLA-A*2402 presenting URLC10-derived peptide and related tumor-associated antigensURLC10-243 peptideUp-regulated in lung cancer 10HLA-A*24:02/URLC10 complexS-288310 target

Induction of antigen-specific cytotoxic T lymphocytes (CTLs) that recognize the URLC10-derived peptide presented by HLA-A*24:02 on tumor cells, leading to targeted cell lysis.